Grant of Options and PDMR Dealing

RNS Number : 2035C

Ondine Biomedical Inc.

21 February 2022

 

21 February 2022

Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")

Grant of Options and PDMR Dealing

 Ondine Biomedical Inc. (AIM: OBI), announces the grant of options to acquire, in aggregate, up to 600,000 common shares (the "Options").

Options to acquire up to 600,000 shares have been granted pursuing to the Ondine Company Share Option Plan. The Options will vest evenly over four years, starting immediately and fully vesting on 4 February 2026. The Options will be exercisable throughout the vesting period and until the 4 February 2027, at a price of £0.54 per new ordinary share.

The Options has been granted to Charles Young, the Company's Vice President Sales & Marketing, North America, and to William Kanz, Vice President Engineering, and the notification below, made in accordance with the UK Market Abuse Regulation, provides further details in this regard. 

PDMR	Position	Number of Shares Under Option	Exercise Price	Vesting Date	Expiry Date
Charles Young	Vice President Sales & Marketing, North America	400,000	£0.54	Fully vested February 4, 2026	February 4, 2027
William Kanz	Vice President Engineering	200,000	£0.54	Fully vested February 4, 2026	February 4, 2027

Following the grant of the Options, the Company has options outstanding over a total of 8,098,000 shares, which represent approximately 4.2% of the Company's existing issued ordinary share capital.

For further Information, contact:

Ondine Biomedical Inc. 

Carolyn Cross, CEO

Telephone: [phone]

Arden Partners plc 

Nominated Adviser and Broker

Ruari McGirr / Antonio Bossi 

Telephone: [phone]

Media Contact:

Simon Vane Percy

Telephone: [phone]

Email: [e-mail] / [e-mail]

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Charles Young
2	Reason for the notification
a)	Position/status	Vice President Sales & Marketing, North America
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ondine Biomedical Inc.
b)	LEI	9845005B69E07CGF4A56
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	S tock Options for Ordinary Shares
b)	Nature of the transaction	Grant of share option under the Ondine Biomedical Company Share Option Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) nil  400,000
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction
e)	Date of the transaction	February 17, 2022
f)	Place of the transaction	Outside of a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	William Kanz
2	Reason for the notification
a)	Position/status	Vice President Engineering
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ondine Biomedical Inc.
b)	LEI	9845005B69E07CGF4A56
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	S tock Options for Ordinary Shares
b)	Nature of the transaction	Grant of share option under the Ondine Biomedical Company Share Option Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) nil  200,000
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction
e)	Date of the transaction	February 17, 2022
f)	Place of the transaction	Outside of a trading venue

 

END

 

 

DSHURRNRUBUUUAR